<tr><td><table  style="background-color:#ffffff;font-family: Arial;" width="550">
    <tr>
        <td width="500" style="padding:15px 25px;">
            <p style="font-size:26px;color:#558476;margin-bottom:5px">
                <strong>Minimal residual disease (MRD) is a prognostic indicator</strong>
            </p>
            <p style="font-size:16px;font-weight:bold;color:#333333">
                MRD status is a key early warning of clinical relapse<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}}</sup>
            </p>
            <p style="font-size:16px;font-weight:normal;color:#333333;font-style:italic;text-align:center">
            Relapse may be the result of the continued presence of MRD in patients, despite achieving a hematologic complete remission<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[2]}}</sup>
            </p>
            <p style="font-size:16px;font-weight:bold;color:#333333;margin-bottom:0">
            Heterogeneity is a major reason that ALL is difficult to manage<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[3]}},{{CitationNumber[4]}}</sup>
            </p>
            <table style="font-family: arial; font-size: 16px;border-collapse: collapse" width="100%" border="0" >
                <tr style="margin-bottom:10px">
                    <td style="color:#558476; vertical-align:top;padding-bottom:10px">&#x25cf;</td>
                    <td style="line-height: 1.333;padding-bottom:10px">MRD testing can uncover leukemic progenitor cells in patients with a hematologic complete response<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}}</sup></td>
                </tr>
                <tr>
                    <td style="color:#558476; vertical-align: top;padding-bottom:10px">&#x25cf;</td>
                    <td style="padding-bottom:10px">Evaluation of bone marrow by microscopic morphological testing cannot identify the presence of leukemic cells if there are fewer than 5% (1 in 20) in the total cell population<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[5]}},{{CitationNumber[6]}}</sup></td>
                </tr>
                <tr>
                    <td style="color:#558476; vertical-align: top">&#x25cf;</td>
                    <td>A substantial proportion of persistent MRD has been reported to consist of slowly dividing progenitor cells that may be resistant to certain therapies<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[4]}},{{CitationNumber[7]}}</sup></td>
                </tr>
            </table>
            <p style="font-size:16px;color:#333333;background: #dfe5e6;margin: 10px 6px; padding:6px;text-align: center;width:490px">MRD testing is routinely performed at specialized treatment centers<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">{{CitationNumber[1]}}</sup>
            </p>
<br>
            
                                <table  cellspacing="0" cellpadding="0" bgcolor="#558476" align="center">
                        
                        <tr><td align="center" style="font-family: arial; padding:15px;padding-bottom:15px;"> <a href="http://www.understandingall.com/understandingmrd.html" target="_blank" style="font-size:22px;color:#eece11;text-decoration:none;vertical-align:middle;"><strong>Find out more about MRD &gt;</strong></a></td></tr>
                    </table>            
            
            
            
            
        </td>
    </tr>
</table>
</td></tr>
{{CitationStart}}
<br><strong>{{CitationNumber[1]}}.</strong> References with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>) for Acute Lymphoblastic Leukemia V.1.2014. Â© National Comprehensive Cancer Network, Inc 2014. All rights reserved. Accessed July 8, 2014. To view the most recent and complete version of the guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, NCCN<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, NCCN GUIDELINES<sup style="font-size: 70%; line-height: 0; position: relative; top: 0.5em; vertical-align: text-top">&reg;</sup>, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc.
<br><strong>{{CitationNumber[2]}}.</strong> Br&uuml;ggemann M, Raff T, Kneba M. <em>Blood.</em> 2012;120:4470-4481.
<br><strong>{{CitationNumber[3]}}.</strong> Pui CH, Relling MV, Downing JR. <em>N Engl J Med.</em> 2004;350:1535-1548.
<br><strong>{{CitationNumber[4]}}.</strong> Zhou Y, You MJ, Young KH, et al. <em>Hum Pathol.</em> 2012;43:1347-1362.
<br><strong>{{CitationNumber[5]}}.</strong> Campana D. <em>Am J Clin Pathol.</em> 2004;122(suppl 1):S47-S57.
<br><strong>{{CitationNumber[6]}}.</strong> G&ouml;kbuget N, Kneba M, Raff T, et al. <em>Blood.</em> 2012;120:1868-1876.
<br><strong>{{CitationNumber[7]}}.</strong> Dick JE. <em>Blood.</em> 2008;112:4793-4807.
{{CitationEnd}}
